Responses to dupilumab (Dupixent) treatment were consistent across racial and ethnic groups in children with atopic ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published ...

A new study published in the Journal of European Academy of Dermatology and Venerology showed that compared to patients on ...

The FDA approved dupilumab (Dupixent ... of which have been shown to co-morbidly occur with CSU -- such as atopic dermatitis and asthma -- providing patients with one treatment that might help ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...

Phase 2b trials in atopic dermatitis and asthma are planned to ... robust STAT6 degradation in blood and skin by KT-621 has a dupilumab-like effect on reducing multiple Th2 biomarkers in the ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Children with early-onset atopic dermatitis (AD) have an elevated risk ... Similar results were seen among patients without dupilumab use (0.08 versus 0.05%; hazard ratio, 1.77) and those without ...

atopic dermatitis, chronic obstructive pulmonary disease, and eosinophilic esophagitis. "Sanofi and Regeneron’s dupilumab approved by FDA for urticaria" was originally created and published by ...